CN110804657A - Application of DIP2C gene in congenital heart disease diagnosis product - Google Patents
Application of DIP2C gene in congenital heart disease diagnosis product Download PDFInfo
- Publication number
- CN110804657A CN110804657A CN201910735521.4A CN201910735521A CN110804657A CN 110804657 A CN110804657 A CN 110804657A CN 201910735521 A CN201910735521 A CN 201910735521A CN 110804657 A CN110804657 A CN 110804657A
- Authority
- CN
- China
- Prior art keywords
- dip2c
- gene
- nucleic acid
- product
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002330 Congenital Heart Defects Diseases 0.000 title claims abstract description 46
- 208000028831 congenital heart disease Diseases 0.000 title claims abstract description 46
- 101150099073 DIP2C gene Proteins 0.000 title claims abstract description 45
- 238000003745 diagnosis Methods 0.000 title abstract description 10
- 241000252212 Danio rerio Species 0.000 claims abstract description 76
- 230000014509 gene expression Effects 0.000 claims abstract description 26
- 230000035772 mutation Effects 0.000 claims abstract description 14
- 238000010171 animal model Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 27
- 101000805870 Homo sapiens Disco-interacting protein 2 homolog C Proteins 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102100037928 Disco-interacting protein 2 homolog C Human genes 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 20
- 238000003018 immunoassay Methods 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 15
- 230000003321 amplification Effects 0.000 claims description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 210000002257 embryonic structure Anatomy 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 7
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 7
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 6
- 239000002853 nucleic acid probe Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical group CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 2
- 210000004789 organ system Anatomy 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 10
- 239000004055 small Interfering RNA Substances 0.000 description 20
- 108020004459 Small interfering RNA Proteins 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 108091027967 Small hairpin RNA Proteins 0.000 description 14
- 230000007547 defect Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000747 cardiac effect Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000002583 angiography Methods 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 238000007901 in situ hybridization Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000009609 prenatal screening Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010061199 Head deformity Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010053652 Limb deformity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- -1 antibodies Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an application of a DIP2C gene in a congenital heart disease diagnosis product, and particularly relates to an application of the expression level of the DIP2C gene and the DIP2C gene, the mutation of the DIP2C gene or the mutation of the DIP2C gene expression product in the congenital heart disease diagnosis product; the invention also provides an animal model of congenital heart disease, and further proves the relationship between the DIP2C gene and congenital heart disease through a zebra fish experiment.
Description
Technical Field
The invention relates to an application of DIP2C gene in the diagnosis product of congenital heart disease.
Background
Congenital Heart Disease (CHD) refers to heart and large blood vessels that exhibit abnormal anatomical structures after birth due to abnormal occurrence and development of the heart and large blood vessels during embryonic development. CHD is the most common birth defect in China at present, and accounts for 1/5-1/4 of all birth defects. CHD not only causes physical and psychological pains to patients, but also causes great economic stress and social burden to families and society.
CHD is clinically manifested in a variety of ways, both in isolated onset and in syndromes. The causes of some syndrome-type CHD are closely related to Copy Number Variations (CNVs). CNVs refer to genomic structural variations of DNA fragments ranging from 1Kb to 3Mb in length, including deletions, insertions, duplications, rearrangements, inversions, changes in DNA copy number, and the like. For example, the main cause of 10p15.3microdeletion syndrome (10p15.3microdeletion syndrome) is the deletion of the copy number of the 10p15.3 segment of the patient's chromosome. The 10p15.3microdeletion syndrome is a rare disease, and patients with the syndrome often have clinical manifestations of special face appearance, developmental retardation, mental retardation, limb deformity, CHD and the like.
Although most CHD can be cured by interventional occlusion and open-heart surgery, the partially simplified CHD patient is usually asymptomatic, and is only discovered after symptoms have appeared, or is discovered accidentally during physical examination, a insidious property that poses a potential threat to quality of life and health. For patients with complicated CHD, the operation effect is not ideal and the fatality rate is extremely high. Such complex CHD patients, particularly those with other clinical manifestations such as mental retardation, can take steps if they can be found early in the fetus, either during cardiac surgery or to avoid the fetus from being born. The method has definite familial hereditary history, and can also adopt means such as test tube babies and the like according to the detection result of parents to block the next generation of hereditary same diseases.
The three points all put higher demands on the early discovery, early diagnosis and early treatment of CHD. Currently, the etiology and pathogenesis of CHD has not been fully elucidated, and prenatal screening and prevention remains a dilemma. Reveals the etiology and pathogenesis of CHD, and reduces the birth rate of CHD children patients becomes a great public health subject. Therefore, an accurate, convenient and cheap CHD early diagnosis tool is searched, which not only can explore the etiology of hereditary CHD, but also can clarify the pathogenesis of CHD, and can provide data support for prenatal screening, prenatal diagnosis and differential diagnosis.
Disclosure of Invention
An object of the present invention is to provide a gene related to CHD.
The invention also aims to provide an application of a preparation, a chip or a kit for detecting the expression level of the DIP2C gene, the expression level of the DIP2C gene, the mutation of the DIP2C gene or the mutation of the expression product of the DIP2C gene in diagnosis of congenital heart disease.
The invention also aims to provide a zebra fish model and application thereof in CHD diagnosis and treatment.
In order to achieve the purpose, the invention adopts the following technical scheme:
the first aspect of the invention provides an expression product of DIP2C gene and DIP2C gene, wherein the DIP2C gene has a nucleotide sequence shown as SEQ ID No.1, and an expression product of DIP2C, DIP2C protein has an amino acid sequence shown as SEQ ID No. 2.
In order to analyze the relationship between CHD and the DIP2C gene, the present invention first analyzes the DIP2C gene of some patients with congenital heart disease and their parents by using the CMA method, and confirms congenital heart disease by cardiac ultrasound, Digital Subtraction Angiography (DSA), magnetic resonance imaging/angiography, or computed tomography.
The second aspect of the present invention provides for the first time the use of the DIP2C gene in a product for the detection of congenital heart disease.
Further, the product comprises a reagent for detecting congenital heart disease by detecting the expression level of DIP2C gene, DIP2C gene, mutation of DIP2C gene or mutation of DIP2C gene expression product in a biological sample.
Further, the detection method of the product is at least one of direct nucleic acid sequencing, nucleic acid molecule hybridization technology, nucleic acid amplification technology, nucleic acid probe technology or immunodetection.
Further, the product comprises a formulation, a chip or a kit.
Further, the detection sample of the product is peripheral blood.
The third aspect of the present invention provides a kit for diagnosing CHD, which comprises at least one pair of DIP2C gene-specific amplification primer pairs, a PCR reaction solution, and at least one nucleic acid probe.
Further, the nucleic acid probe is SYBR Green I, a Taqman probe, a molecular beacon, a hybridization probe or a composite probe.
Further, the DIP2C gene specific amplification primer pair has nucleotide sequences shown as SEQ ID NO.3 and SEQ ID NO. 4.
In a fourth aspect of the present invention, there is provided a method for constructing an animal model of congenital heart disease, comprising administering a DIP2C inhibitor to a culture system, wherein the culture system comprises a cell system, a subcellular system, a solution system, a tissue system, an organ system, or an animal system.
Further, a DIP2ca gene inhibitor homologous to the human DIP2C gene was injected into zebrafish embryos.
Further, the inhibitors are antisense morpholine antisense oligonucleotides MO1 (against exon 4-intron 4 splicing region) and MO2 (against ATG site) having the sequence of SEQ ID No.5 or SEQ ID No. 6.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only one embodiment of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
Fig. 1 is CMA results and clinical cardiac ultrasound diagnosis of patients carrying a microdeletion of DIP 2C;
FIG. 2 is a statistical plot of normal gross phenotype and number of phenotypes of zebrafish;
FIG. 3 is a cardiovascular phenotype of zebrafish;
FIG. 4 shows the result of detecting the expression level of dip2ca mRNA in zebra fish CHD model.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The mutation of DIP2C gene includes base substitution mutation, frame shift mutation, deletion mutation and insertion mutation of DIP2C gene, and the mutation of DIP2C gene expression product includes expression product of DIP2C mutant gene.
Methods for detecting the expression level of DIP2C include, but are not limited to: polymerase Chain Reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), Transcription Mediated Amplification (TMA), Ligase Chain Reaction (LCR), Strand Displacement Amplification (SDA) and Nucleic Acid Sequence Based Amplification (NASBA), In Situ Hybridization (ISH), chromosomal microarray expression profiling, Southern or Northern blotting, sandwich ELISA, Radioimmunoassay (RIA), direct, indirect or contrast enzyme-linked immunosorbent assay (ELISA), Enzyme Immunoassay (EIA), Fluorescence Immunoassay (FIA), western blotting, immunoprecipitation, and any particle-based immunoassay (e.g. using gold, silver or latex particles, magnetic particles or quantum dots). Among them, PCR requires reverse transcription of RNA into DNA before amplification (RT-PCR), TMA and NASBA to directly amplify RNA. Detecting the expression level of a gene "refers to determining the presence of mRNA of a marker gene in a biological sample and its expression level in order to predict CHD occurrence and can be accomplished by measuring the amount of mRNA. Analytical methods for this purpose are, but are not limited to, RT-PCR, competitive RT-PCR, Real-time RTPCR, RNase Protection Assay (RPA), Northern blotting, DNA microarray chips, etc.
Methods for detecting gene mutations or protein mutations include, but are not limited to: PCR-SSCP method, heteroduplex analysis method, denaturation gradient gel electrophoresis method, chemical cutting mismatch method, allele specific oligonucleotide analysis method, DNA chip technology, ligase chain reaction, allele specific amplification method, direct sequencing method.
In the present invention, the formulation can determine the presence of mRNA in a sample on a test strip, membrane, chip, disk, test strip, filter, microsphere, slide, multiwell plate, or fiber optic. The assay system can have a solid support to which a nucleic acid corresponding to mRNA is attached. The solid support may comprise, for example, a plastic, a silicon wafer, a metal, a resin, a glass, a membrane, a particle, a precipitate, a gel, a polymer, a sheet, a sphere, a polysaccharide, a capillary, a film, a plate, or a slide. The assay components can be packaged together after manufacture as a kit for detecting mRNA.
Nucleic acid hybridization techniques of the present invention include, but are not limited to, in situ hybridization (FISH), chromosomal microarrays, and Southern or Northern blots. In Situ Hybridization (FISH) is a hybridization of specific DNA or RNA sequences in a tissue section or section using a labeled complementary DNA or RNA strand as a probe (in situ) or in the entire tissue if the tissue is small enough (whole tissue embedded ISH). DNAISH can be used to determine the structure of chromosomes. Rnash is used to measure and locate mRNA and other transcripts (e.g., ncRNA) within tissue sections or whole tissue embedding. Sample cells and tissues are typically treated to fix the target transcript in situ and to increase probe access. The probe is hybridized to the target sequence at high temperature, and then excess probe is washed away. The localization and quantification of base-labeled probes in tissues labeled with radiation, fluorescence or antigens is performed using autoradiography, fluorescence microscopy or immunohistochemistry, respectively. ISH can also use two or more probes labeled with radioactive or other non-radioactive labels to detect two or more transcripts simultaneously.
In the present invention, the immunoassay can be based on any of the following methods:
immunoprecipitation (Immunoprecipitation): immunoprecipitation is the simplest immunoassay method; this method measures the amount of precipitate that is formed after the reagent antibody has been incubated with the sample and reacted with the target antigen present therein to form insoluble aggregates. The immunoprecipitation can be either qualitative or quantitative.
Particle immunoassay: in a particle immunoassay, multiple antibodies are attached to the particle and the particle is capable of binding many antigenic molecules simultaneously. This greatly accelerates the speed of the visible reaction. This allows for a fast and sensitive detection of the biomarker.
Immunoturbidimetry (immunonephelometry): in immunoturbidimetry, the interaction of the antibody and the target antigen on the biomarker causes the formation of an immune complex that is too small to precipitate. However, these complexes will scatter incident light, which can be measured using a turbidimeter. The concentration of the antigen (i.e. biomarker) can be determined within a few minutes of the reaction.
Radioimmunoassay (RIA): radioimmunoassays use radioisotopes such as I125 to label antigens or antibodies. The isotope used emits gamma rays, which are usually measured after removal of unbound (free) radiolabel. The main advantages of RIA compared to other immunoassays are higher sensitivity, easy signal detection and confirmation, fast assay. The main disadvantages are the health and safety risks posed by the use of radiation and the time and expense associated with maintaining the licensed radiation safety and disposal procedures. For this reason, RIA has been largely replaced by enzyme immunoassays in routine clinical laboratory practice.
Enzyme Immunoassay (EIA): enzyme immunoassays use enzymes to label antibodies or target antigens. The sensitivity of EIA is close to that of RIA and there is no risk caused by radioisotopes. One of the most widely used EIA methods for detection is enzyme-linked immunosorbent assay (ELISA). The ELISA method may use two antibodies, one specific for the target antigen and the other coupled to an enzyme, the addition of an enzyme substrate causing the generation of a chemiluminescent or fluorescent signal.
Fluorescence Immunoassay (FIA): fluorescence immunoassay refers to an immunoassay that uses a fluorescent label or an enzyme label that acts on a substrate to form a fluorescent product. Fluorescence measurements are inherently more sensitive than chromatic (spectrophotometric) measurements. Thus, the FIA method has higher analytical sensitivity than the EIA method using absorption (optical density) measurement.
Chemiluminescence immunoassay: chemiluminescent immunoassays (CLIA) use a chemiluminescent label that produces light when excited by chemical energy; the emission is measured using a photodetector.
In the present invention, the inhibitor of DIP2C refers to any substance that can decrease the activity of DIP2C protein, decrease the stability of DIP2C gene or protein, down-regulate the expression of DIP2C protein, decrease the effective duration of DIP2C protein, or inhibit the transcription and translation of DIP2C gene, and can be used in the present invention, for example, the inhibitor is: nucleic acid inhibitors, protein inhibitors, antibodies, ligands, proteolytic enzymes, protein binding molecules, as long as they are capable of down-regulating the expression of DIP2C protein or its encoding gene at the protein or gene level.
Wherein the nucleic acid inhibitor is selected from: an interfering molecule which uses DIP2C or a transcript thereof as a target sequence and can inhibit the expression or the transcription of a DIP2C gene, comprising: shRNA (small hairpin RNA), small interfering RNA (sirna), dsRNA, microrna, antisense nucleic acid, or a construct capable of expressing or forming said shRNA, small interfering RNA, dsRNA, microrna, antisense nucleic acid. The protein binding molecule is selected from: a substance that specifically binds to DIP2C protein, such as an antibody or ligand that inhibits the activity of DIP2C protein.
In an alternative embodiment of the invention, the inhibitor of DIP2C is an antibody that specifically binds to DIP 2C. The specific antibody comprises a monoclonal antibody and a polyclonal antibody; the invention encompasses not only intact antibody molecules, but also any fragment or modification of an antibody, e.g., chimeric antibodies, scFv, Fab, F (ab') 2, Fv, etc. As long as the fragment retains the ability to bind to DIP2C protein. The preparation of antibodies for use at the protein level is well known to those skilled in the art and any method may be used in the present invention to prepare such antibodies.
As an alternative embodiment of the present invention, the inhibitor of DIP2C is a DIP2C specific small interfering RNA molecule. As used herein, the term "small interfering RNA" refers to a short segment of double-stranded RNA molecule that targets mRNA of homologous complementary sequence to degrade a specific mRNA, which is the RNA interference (RNA interference) process. Small interfering RNA can be prepared as a double-stranded nucleic acid form, which contains a sense and an antisense strand, the two strands only in hybridization conditions to form double-stranded. A double-stranded RNA complex can be prepared from the sense and antisense strands separated from each other. Thus, for example, complementary sense and antisense strands are chemically synthesized, which can then be hybridized by annealing to produce a synthetic double-stranded RNA complex.
As an alternative of the present invention, the inhibitor of DIP2C may also be a "Small hairpin RNA (shRNA)" which is a non-coding Small RNA molecule capable of forming a hairpin structure, and the Small hairpin RNA can inhibit gene expression via RNA interference pathway. As described above, shRNA can be expressed from a double-stranded DNA template. The double-stranded DNA template is inserted into a vector, such as a plasmid or viral vector, and then expressed in vitro or in vivo by ligation to a promoter. The shRNA can be cut into small interfering RNA molecules under the action of DICER enzyme in eukaryotic cells, so that the shRNA enters an RNAi pathway. "shRNA expression vector" refers to some plasmids which are conventionally used for constructing shRNA structure in the field, usually, a "spacer sequence" and multiple cloning sites or alternative sequences which are positioned at two sides of the "spacer sequence" are present on the plasmids, so that people can insert DNA sequences corresponding to shRNA (or analogues) into the multiple cloning sites or replace the alternative sequences on the multiple cloning sites in a forward and reverse mode, and RNA after the transcription of the DNA sequences can form shRNA (short Hairpin) structure. The "shRNA expression vector" is completely available by the commercial purchase of, for example, some viral vectors.
In a preferred embodiment of the present invention, the inhibitor of DIP2C is an antisense oligonucleotide, which refers to an RNA or DNA fragment having a sequence complementary to an RNA sequence in vivo and capable of hybridizing to a complementary strand by base pairing, thereby affecting the transcription or translation process. More preferably, the inhibitor is a morpholine antisense oligonucleotide, which is named after a morpholine ring on its nucleotide backbone, replacing a ribonucleotide ring in RNA or a deoxyribonucleotide ring in DNA. Morpholine antisense oligonucleotide is a novel antisense oligonucleotide capable of inhibiting the splicing process of mRNA in cells, thereby inhibiting the expression of genes; meanwhile, the product has good stability, solubility and cell permeability.
To achieve the above object, the present invention first analyzes some patients with congenital heart disease and their parents with the CMA method for their DIP2C gene, and confirms congenital heart disease by cardiac ultrasound, Digital Subtraction Angiography (DSA), magnetic resonance imaging/angiography, or computed tomography.
And (3) CMA detection:
1. collecting samples:
patients diagnosed with CHD at the Guangdong provincial hospital during the 11 th to 2018 th months in 2015 were collected. Patients commonly incorporate a particular facial appearance, mental development disorders and/or behavioral disorders. (blood was retained for patient and their biological parents, patient + biological parents as core family). The diagnosis of CHD is confirmed by cardiac ultrasound, Digital Subtraction Angiography (DSA), magnetic resonance imaging/angiography, or computed tomography. All parents underwent physical examination to confirm clinical performance.
The study was approved by the ethical committee of the people's hospital of Guangdong province. The patient or his parent sign informed consent. The zebrafish experiment was approved by the animal protection and application committee (IACUC) of the national hospital of people, guangdong province.
2. And (3) sample analysis:
2.1DNA extraction: the whole genome DNA of the peripheral blood of a patient and parents is extracted by using a blood genome DNA extraction kit of Tiangen, and the DNA is quantitatively detected by using 1 percent agarose gel electrophoresis and a Nanodrop 2000 spectrophotometer.
2.2CMA detection: all specimens were tested using the Affymetrix chip test platform and AffymetrixCytoscan HD chips. ChAS 2.1software for analysis.
3. And (3) detection results:
the results are shown in figure 1, CMA results show that patients harbor a microdeletion containing the DIP2C gene.
4. Constructing a zebra fish model:
4.1 zebrafish line:
AB strain
4.2 in vitro transcription and embryo injection:
an antisense morpholine antisense oligonucleotide was designed comprising MO1 (for exon 4-intron 4 splicing region) having the nucleotide sequence SEQ ID No.5 and MO2 (for ATG site) having the nucleotide sequence SEQ ID No. 6.
Meanwhile, a control group was prepared using MO3 having the nucleotide sequence of SEQ ID NO. 7.
Zebrafish morphology control experiment 1:
injecting MO1 into cells from a single cell stage to a two cell stage of a plurality of zebra fish embryos, wherein 4ng of each cell is injected, and an inhibition group containing 116 dip2ca genes for inhibiting zebra fish is obtained after 48 hours;
MO3 was injected into cells from the unicellular stage to the bicellular stage of zebra fish embryos, 4ng of each cell was injected, and an inhibition control group containing 116 zebra fish was obtained 48 hours later;
zebrafish morphology control experiment 2:
MO1 was injected into cells from a single-cell stage to a two-cell stage of multiple zebra fish embryos, and 4ng of each cell was injected for 48 hours to obtain a rescue inhibition group containing 102 dip2ca genes for inhibiting zebra fish;
MO3 is injected into cells from a zebra fish embryo in a single cell stage to a two-cell stage, and a rescue control group containing 108 zebra fish is obtained after 4n of injection for 48 h;
MO1 and wild-type zebrafish dip2ca mRNA were injected into the zebrafish embryonic cells from the one-cell stage to the two-cell stage, 4ng of MO1 and 4ng of wild-type zebrafish dip2ca mRNA were injected into each cell, and a rescue group containing 96 zebrafish was obtained 48h later.
4.3 Observation under the mirror
The egg membranes of the zebra fish in the inhibition group and the zebra fish in the control group are stripped by using tweezers, and the zebra fish in the control group are anesthetized by using Tricane. Embryos were fixed in low-melt glue, photographed using a confocal microscope, and zebrafish cerebrovascular phenotypes were assessed using a blinding method by two researchers. The zebra fish brain vessel phenotype is shown in figure 3.
4.4 results
The morphology and statistics of zebrafish are shown in fig. 2, wherein,
(A) representing inhibition of zebrafish posture in the control group:
(B) zebrafish posture, which represents a mild developmental defect in the inhibited group:
(C) zebrafish posture, which represents a severe developmental defect in the inhibited group:
(D) histograms show the proportion of embryo developmental disorders;
inhibiting the normal development of zebra fish in the control group; 43.10% (50) of the inhibited group of zebrafish showed mild developmental defects, and 56.90% (66) of the inhibited group of zebrafish showed severe developmental defects;
(E) comparing the body lengths of the zebra fish in the inhibition group and the zebra fish in the inhibition control group; inhibition control group: 3.287 +/-0.0525 mm; inhibition of mild developmental defects in the group zebrafish: 2.905 + -0.1034 mm; zebrafish with severe developmental defects in the group were inhibited by 1.288 ± 0.1470mm (mean ± sd,. p < 0.05);
(F) representing the posture of the zebra fish in the rescue control group;
(G) representing the posture of the zebrafish in the rescue-inhibited group;
(H) representing the posture of normally developing zebrafish in the rescue group;
(I) histogram shows the proportion of dysplastic embryos in the rescue experiment:
saving the control group, wherein the zebra fish all normally develop; 45.09% (46) of rescue inhibited zebra fish showed mild developmental defect, 54.91% (56) of rescue inhibited zebra fish showed severe developmental defect; 31.25% (30) of the rescued zebrafish, which developed normally, 22.92% (22) of the rescued zebrafish, which exhibited mild developmental defects, and 45.83% (44) of the rescued zebrafish, which exhibited severe developmental defects;
(J) comparing the embryo lengths of the zebrafish of the rescue inhibition group, the rescue control group and the rescue group; rescue group normally developing zebrafish and rescue control group: 3.466 + -0.0263 mm; zebrafish with mild developmental defects in rescue-inhibited and rescue groups: 2.443 +/-0.2091 mm; rescue of zebrafish with severe developmental defects in the suppressor and rescue groups: 1.430 + -0.2786 mm. (mean ± standard deviation,. p < 0.05).
The cardiovascular phenotypic analysis of zebrafish is shown in FIG. 3, wherein
(A) Representing the normal developing zebrafish cardiovascular phenotype in the suppressed control group and the rescue control group;
(B) a zebrafish cardiovascular phenotype indicative of a moderate developmental defect;
(C) a zebrafish cardiovascular phenotype indicative of a severe developmental defect;
(D) representing a cardiovascular phenotype of normally developing zebrafish in the rescue group.
4.5 conclusion:
(1) zebrafish phenotypic analysis showed that zebrafish exhibited head deformity, body segment deformity and shortened body length compared to the inhibition control group (fig. 2A-C). Statistics on the number of zebra fish revealed that the inhibition group had a significantly increased number of zebra fish developmental malformations compared to the control group (fig. 2D, E). And rescue experiments show that exogenous dip2ca mRNA can improve the development condition of the zebra fish with the dip2ca gene inhibited (FIG. 2F-H). Statistics on the number of zebra fish in the rescue experiment shows that the number of developmental malformations of the zebra fish in the rescue experiment group is remarkably reduced (fig. 2I, J), and further proves the role of the dip2ca gene in development.
(2) Phenotypic analysis of the cardiovascular system of zebrafish revealed that the dip2ca-MO group exhibited a range of cardiac malformation characteristics: (1) pericardial edema; (2) prolongation of cardiac vessels, dysfunction of cardiac vessel cyclization and reduced cardiac contractility (fig. 3A-C); rescue experiments clearly reversed the cardiac phenotype and overall morphology of dip2ca-MO, further demonstrating the role of dip2ca in development (fig. 3D).
5. Statistical analysis
5.1RNA extraction
MO1 (targeting exon 4-intron 4 splicing region), MO2 (targeting ATG site) and MO3 were injected into multiple zebrafish embryonic single-cell to two-cell cells, and 4ng of each cell was injected to obtain E4I4-MO group zebrafish, ATG-MO group zebrafish and Control-MO group zebrafish.
Total RNA from 24h embryos was extracted using Trizol method, and the tissues or cells were homogenized and added to 1.5ml centrifuge tubes. Chloroform of 0.2 times the same volume was added, and the mixture was shaken and mixed for 30 seconds. Centrifuge at 15000g for 3min at room temperature. The supernatant was transferred to another clean centrifuge tube. Equal volume of isopropanol was added to the supernatant and mixed on a shaker for 30 s. Centrifugation at 15000g for 5min at room temperature resulted in RNA pellet formation on the side of the bottom of the centrifugation and the supernatant was carefully aspirated off. Cleaning: 1ml of 75% ethanol was added to the centrifuge tube containing the RNA pellet and mixed on a shaker for 30 seconds. Centrifuge at 15000g for 1min at room temperature. The supernatant was carefully aspirated. The washing step is repeated. The centrifuge tube was inverted on filter paper to dry the RNA.
Reverse transcription of RNA
The RNA product was subjected to Reverse transcription using the OneScript Reverse Transcriptase kit, and the Reverse transcription product was subjected to PCR amplification. The primer has a dip2ca gene specificity amplification primer pair with nucleotide sequences shown as SEQ ID NO.3 and SEQ ID NO. 4:
and (3) PCR reaction conditions: 94 ℃ for 2min, (94 ℃ for 30s, 60 ℃ for 30s, 72 ℃ for 1.5min) x 25-30 cycles.
6. Statistical analysis
The sequence of the detection probe is shown in SEQ ID NO. 8. All experiments were performed in at least three replicates and statistical analysis was performed using SPSS23.0 software. Statistically significant is defined as P < 0.05. Zebra fish phenotypic ratio data were analyzed using the t-test.
As shown in FIG. 4, the ordinate represents the expression level of dip2ca mRNA, and the expression level of Control-MO group zebra fish is 1, it can be seen that the expression levels of dip2ca mRNA of E4I4-MO group zebra fish and ATG-MO group zebra fish are greatly reduced, and MO1 and MO2 can be considered to play an effective inhibition role on the dip2ca gene of zebra fish, and can be used for the construction of the zebra fish CHD model.
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, it is possible to make several improvements and modifications to the present invention without departing from the principle of the present invention, and those improvements and modifications are also included in the scope of the present invention as claimed.
<110> institute of cardiovascular disease of Guangdong province
Application of <120> DIP2C gene in congenital heart disease diagnosis product
<160>8
<210>1
<211>8121
<212>DNA
<213> Artificial sequence
<220>
<223> DIP2C Gene
<400>1
1 gcgcccgccg cccgcctccc gcgcccgcgc cgccgcctcc tcctcggtgc ggttccgccg
61 ggcgcgagga gccgccgaga cctccgcctg cgaacaaaga ggaggccgtg cggggcgcgg
121 cgcccgcgga gcatggcgga ccgcagcctg gagggcatgg cgctgcccct ggaggtgcgg
181 gcgcgcctgg ccgagctgga gctggagctg tcggaaggtg acatcacaca aaaaggatat
241 gaaaagaaga ggtcaaagtt aattggagcc taccttccgc agcctccgac agcgaatgga
301 gctgccgtgg ttcggtgtag actgcagcac agtgaaggag cgccgaggag aacattccgc
361 tctgcccaca tcggggtgtg cgacgtccga gaagctgcgg ctcgggagcg ggtggccagc
421 accgcaggga accggcctct gttttacttt cgtttcgggg tggaccaagc tttgccgcaa
481 gaacgccggg ctcctgtcac tccttcctcc gcctctcgct accaccgccg acggtcttca
541 gggtcacgag atgagcgcta tcggtcagac gtccacacgg aagctgtcca ggcggctctg
601 gccaaacaca aagagcggaa gatggcagtg cctatgcctt ccaaacgcag gtccctggtc
661 gtgcagacct cgatggacgc ctacacccct ccagatacct cttctggctc agaagatgaa
721 ggctcagtgc agggggactc ccagggcacc cccacctcca gccagggcag catcaatatg
781 gagcactgga tcagccaggc catccacggc tccaccacgt ccaccacctc ctcgtcctct
841 acgcagagcg ggggcagcgg ggctgcccac aggctggcgg acgtcatggc tcagacccac
901 atagaaaatc attctgcacc tcctgacgta accacgtaca cctcagagca ctcgatacag
961 gtggagagac cgcagggttc cacggggtcc cggacagcgc ccaagtacgg caacgccgag
1021 ctcatggaga ccggggatgg agtaccagta agtagccggg tgtcagcaaa aatccagcag
1081 cttgtcaata ccctcaaacg accgaaacga ccacctttac gagaattctt tgtcgatgac
1141 tttgaagaat tattagaagt tcaacaaccg gatccgaacc aaccaaagcc ggagggggcc
1201 cagatgctgg ccatgcgcgg agagcagctg ggcgtggtca cgaactggcc gccgtcgctg
1261 gaggccgcac tgcagaggtg gggcaccatc tcgcccaagg cgccctgcct gaccaccatg
1321 gacaccaacg ggaagcccct ctacatcctc acttacggca agctgtggac aagaagtatg
1381 aaggtcgctt acagcattct acacaaatta ggcacaaagc aggaacccat ggtccggcct
1441 ggagataggg tggcactggt gttccccaac aatgatccgg ctgccttcat ggcggctttc
1501 tacggctgcc tgctggccga ggtggtcccc gtgcccatcg aggtgccgct caccaggaag
1561 gacgcaggga gccagcagat aggtttcttg cttggaagct gtggagttac tgtagccttg
1621 actagtgacg cctgccataa aggacttcca aaaagcccaa cgggagagat cccacagttt
1681 aaaggttggc caaagctgct gtggtttgtc acagagtcta aacatctctc caaaccgccc
1741 cgagactggt tcccacacat taaagatgcc aataacgaca ctgcgtatat tgagtacaag
1801 acgtgtaagg atggcagtgt gctgggtgtg acggtgacga ggactgcgct gctgacacac
1861 tgccaggccc tgacgcaggc gtgtggctac acggaagctg aaaccattgt gaatgtgctg
1921 gatttcaaga aggacgtcgg gctctggcat ggcatcctga caagcgtcat gaacatgatg
1981 catgtgatca gcatcccgta ctcgctgatg aaggtgaacc ctctctcctg gatccagaag
2041 gtctgccagt acaaagcaaa agtggcgtgt gtgaaatcga gggatatgca ttgggcatta
2101 gtagcacaca gagatcagag agacatcaac ctctcctctc tgcgaatgct gatagtggcg
2161 gacggcgcga acccctggtc tatttcttct tgcgatgcat ttctcaatgt cttccaaagt
2221 aaaggccttc gacaggaggt catctgtcct tgtgccagct cgccagaggc cctcactgtg
2281 gccatccgga ggcccacgga tgacagtaac cagcccccgg gccggggtgt cctctccatg
2341 catggactga cctatggggt cattcgtgtg gactcggaag agaagctgtc cgtgctcacc
2401 gtgcaggatg tcggcctcgt gatgcctgga gccatcatgt gttcagtgaa gccagacggg
2461 gttcctcagc tgtgcagaac ggatgagatc ggggagctgt gtgtgtgtgc agttgcgacg
2521 ggcacgtcct actatggcct ctctggcatg accaagaaca cctttgaggt gtttcccatg
2581 acaagctccg gggctccgat cagtgaatac ccattcataa ggacaggctt gctggggttc
2641 gtgggtcccg gaggcctcgt cttcgtggtg ggcaagatgg atggcctcat ggtggtcagc
2701 gggcgcaggc acaacgccga cgacatcgtg gccactgcgc tggccgtaga acccatgaag
2761 tttgtctacc ggggaaggat agccgtgttc tcggtgaccg tgctgcacga cgagaggatc
2821 gtgatcgtgg ctgagcagag gcctgactcc acggaagagg acagtttcca gtggatgagc
2881 cgtgtgctgc aggcgattga cagtatacat caagttggag tttattgcct ggccttggtg
2941 ccagcaaaca ccctccccaa aaccccgctt ggtgggatcc atttatcaga aacaaaacag
3001 ctttttctgg agggctctct gcacccctgc aatgtcctaa tgtgccccca cacctgcgtc
3061 acaaacttgc ctaagcctcg acagaagcag ccagaaatcg gccctgcctc tgtgatggtg
3121 gggaacctgg tctctgggaa gagaatcgcc caggccagtg gcagagacct gggtcagatc
3181 gaagataacg accaggcacg caagttcctg ttcctctcag aggtcttgca gtggagagca
3241 cagaccaccc cggaccacat cctctacacg ctgctcaact gtcggggtgc gatagcgaac
3301 tcgctgacct gcgtgcagct gcacaagaga gctgagaaga tcgccgtgat gctgatggag
3361 aggggccacc ttcaggacgg cgaccacgtg gccttggtct accccccagg aatagacctg
3421 atagcagcgt tttatggttg cctgtacgca ggctgtgtgc caataaccgt ccgtcccccg
3481 cacccacaga acatcgcgac gacgttgcct accgtcaaga tgattgtgga ggtgagtcgc
3541 tctgcctgtc tgatgacgac acagctgatc tgtaagttgc tgcggtccag ggaggcggcg
3601 gcggctgtgg acgtcaggac gtggcccctc atcctggaca cagatgattt gccaaagaag
3661 cggcctgccc agatctgcaa accttgcaac ccagacactc ttgcatatct cgacttcagc
3721 gtgtccacaa ctgggatgct agctggcgta aagatgtctc acgcagccac cagtgccttc
3781 tgccgttcca ttaagctgca gtgtgaactt tacccctcta gagaagtggc catctgcctg
3841 gacccttact gtggactggg atttgtcctc tggtgcctct gcagtgtgta ttctgggcac
3901 cagtccatcc tgatcccgcc ctctgagctg gaaaccaacc ccgccttgtg gcttcttgcc
3961 gtgagtcagt acaaagtccg agacacgttt tgctcctact ccgtgatgga gctgtgcacc
4021 aaggggctgg gctcgcaaac agagtccctc aaggcgcgag ggctggactt gtcccgagtg
4081 aggacctgcg tggttgtggc ggaagagagg cctcggatcg cactcacaca gtcgttctca
4141 aagctgttta aggacctggg ccttcacccg cgggccgtca gcacctcgtt cggttgcagg
4201 gtgaacctgg cgatttgctt gcagcctcac aggctgtgga ccctggccga gcagggaacc
4261 tcaggacctg acccaaccac tgtctacgtg gacatgagag ccctgagaca cgacagagtc
4321 cgcttagtgg aaagaggatc ccctcatagt ctgcccctga tggaatcggg aaagatactt
4381 ccaggggttc ggattataat tgccaaccca gaaacaaaag gaccgctggg ggactcacac
4441 cttggagaga tttgggttca cagtgcccac aatgccagcg gttatttcac tatttacgga
4501 gacgaatccc tccagtcaga tcacttcaac tcaagactaa gttttggaga cacccagacc
4561 atctgggcac gcacaggcta cttggggttc ctgcggagaa ctgagctcac agatgcaaat
4621 ggagagcgcc atgatgccct ctacgtggta ggggcactgg acgaagccat ggagctgcgg
4681 ggcatgcggt accacccaat cgacattgag acctcggtca tcagagccca taaaagcgtt
4741 acggaatgtg ctgtgtttac ctggacaaat ttgttggtgg ttgtggttgagctggatggg
4801 tcggaacaag aagccttgga cctggttccc ttggtgacca acgtggtcct ggaggagcac
4861 tacctgatcg tcggagtggt ggtcgtggtg gacatcggcg tcatccccat caactcccgt
4921 ggggagaagc agcgcatgca cctgcgagac gggtttttgg cagaccagct agaccccatc
4981 tatgtggcct acaacatgta gtctcgtctc ttggcttcca tggacttttc tagagatgta
5041 gacattgttc tccgtgtcca ctgaagcgtg cagacacagg gcaacactca ccagaataca
5101 gccatttgtg gtgagagtgg aggaggaaga ggaggaggaa gaggacttct cacagcagcc
5161 acgattggca tgggggtgaa atgtgaattt accactgaat ttcgctcaga aggactttgg
5221 attactgcct tcagtttgtt ggaaaagccc atttcaaaac tttcttttct tttctttctt
5281 ttttaattat tggataataa gtgctttctt cgtaaatgtg gtattttgtt aagccgaaat
5341 agcaattaaa aaaatatcct gccctccaga tgggttcttt taaacaattt atgtagtgtg
5401 acaaagaatt gttttctctg ttttaatgtg tcatgaaatc ttaatgacat ggatctgtta
5461 ctaatttaag ccattgctag atctcatcct tttaggaaag tttgaggtac gagaaaacct
5521 tccaaatagc accttccaat tagataatag cagctttctt tgtcagaaat gtgctgaaga
5581 aacaaaggct ggtatacggc cttcgaagtt agtatagaat gagaagaaat tataaataag
5641 gtgtatttcg gcaattatct tgcaaatatc tttgtactaa actaaaaaga taaaataagt
5701 taacttcctc aatatgtaat tatgtacaaa acgtttaatt tattttgatc tctttagaac
5761 tataaaagag aaaaacattc aagaatatta aagtcttgta atgtttgcta atataaaaaa
5821 gtgttgtatt atcttgcgtg gatagtatca caacaaatat atatatatga aatataaatt
5881 cactaatgaa caaaggagat tttaaagttt aagatgcaga acttgtcact tgcatggtgt
5941 gccccccgta ctcacataca ctctgctgtt gccagcagtc gcagaccgca ggagccctgt
6001 ctaaaagttt cttctagaac cagagaccag caagtgaaat tattgccatc tcaaggatgg
6061 caaaagaatt caaagctcaa tgtgcactat ttttttcttt gctgtgggac aacagtgaat
6121 gtgtttatgc cagcgtgtgc tgatgatact gaggggcttt aggttggcaa atagcactgt
6181 tttcttagct gcaagaattc attgcacaat gtttttcatc atttttgtta atgtcatctt
6241 tttttggtcc ttgctacgaa aaggaatgcg attctgtggt cattcgcact gggttgcatt
6301 gattccccct ctgatggcca atgtggagtg gacaaagtgt ccggaactca catcggtgat
6361 cgtcccctcg tcttaagacc cagcccgctc tgtgtgagcc tctggggctc cctcgctcag
6421 tgagcacagt tccccggggg ttcatgccag agctccggct gaagcaagaa gtcctccagc
6481 tgcgtcgttt gccgcctgtg gacgagtgcg ccccagtttc tgccctggca gctcctggcc
6541 acaccttctc agagctcacc tgtgcacttc taaattgaat tggcccacgg tgtccaacca
6601 agaaggagca tctgcactcc gagaaagatg tgttctgtaa ctgccccagt gtgaccccgc
6661 agtggctctc ggtgctagat atgcatgact aagattgatg ctgggcaaaa tgtagatgat
6721 ctttcattat gttgtgggca gcgtctttct ctgcctttgc tatatgcagt cagcagtaag
6781 ccttttgcta aaagagtttt gtttgacttc tgagatccaa ggctgattgt tgttaaaaaa
6841 aaaaaaaaaa aaaaagtggc acatttaaaa aaatgtgtct gcatatgtgg tgcatccttc
6901 catctccaca aaccatttga ttcttgaaat attgtttgac ctcattgctg tgtgtgaata
6961 tttctccaca tgcttcagat gcacattcct agtctctgct tcctaagggg ggaaccacca
7021 cacattgggg ggaaaaaaga cattttccta cacccaccca ccttgttgaa agggaggtag
7081 gtttggggct tcaggccagg cactgactat gaaacattag ctgcagtgtg caggacagct
7141 ttgaggtcca gctgaagtca ggaagcaaaa caaatgtaga tgtcacttca aacataattt
7201 caactgtcac cagatcaact ctacattcaa ggagtgtgga cgctgcagtg cagttgtgag
7261 ggcagttagc agccgcctct tctgcatcct gtcaactctg attagttaga gtttaggctc
7321 aaaagagttg gtggactgag attgaaattt ggttgtgcaa gagaaaggaa aggagacact
7381 tagtaccacc agtttcagca ataaagaagg gtcattctgt attcaaaatt gtactgtaga
7441 taaatcattc atgagattgt aaaaaatgtt tgtcttgtga ccttgtgctt ttgaagtcag
7501 acaaaaccgt gtaatcaact tgcacaaaaa gagggtacac agtgaacata taaacacaga
7561 cctaatcaaa caggagcaga ttcctcatgg tgcttgttta ttatatatat ttaatcctgc
7621 ttgacacttt acccaaggga gatggtccct tttatcagtt gaatgttagc agcgttattt
7681 cagagtgtgg tgactggtta gagaaactca tgtactcaac cagccacagt ttcaaacaaa
7741 atttttatgt gcaaaggaca gcaaccttct tgtatgttaa accaccagta cgctttgtac
7801 atctgtgata acgcctgttt tatattcaaa tgaacaaata aaagctttta tttttgttgc
7861 tctgaaaata gcagtttctt aattggtccc ctggaaagat gtctgggaca gctttaatcc
7921 cgggaaggaa gtgactccta cagggaaatg tatctgactc tgtttacata atttgttgca
7981 ttacttagta cagataatca tactttgaaa aatgtttaaa ttttgatgtg ggcatttatt
8041 gctaaaaata attcctatgg caacaaatgt tttgtgaaat gtttttttta attcttttaa
8101 atatatctaa atatatttgt tc
<210>2
<211>1556
<212>PRT
<213> Artificial sequence
<220>
<223> DIP2C Gene expression product
<400>2
1 MADRSLEGMA LPLEVRARLA ELELELSEGD ITQKGYEKKR SKLIGAYLPQ PPRVDQALPQ
61 ERRAPVTPSS ASRYHRRRSS GSRDERYRSD VHTEAVQAAL AKHKERKMAV PMPSKRRSLV
121 VQTSMDAYTP PDTSSGSEDE GSVQGDSQGT PTSSQGSINM EHWISQAIHG STTSTTSSSS
181 TQSGGSGAAH RLADVMAQTH IENHSAPPDV TTYTSEHSIQ VERPQGSTGS RTAPKYGNAE
241 LMETGDGVPV SSRVSAKIQQ LVNTLKRPKR PPLREFFVDD FEELLEVQQP DPNQPKPEGA
301 QMLAMRGEQL GVVTNWPPSL EAALQRWGTI SPKAPCLTTM DTNGKPLYIL TYGKLWTRSM
361 KVAYSILHKL GTKQEPMVRP GDRVALVFPN NDPAAFMAAF YGCLLAEVVP VPIEVPLTRK
421 DAGSQQIGFL LGSCGVTVAL TSDACHKGLP KSPTGEIPQF KGWPKLLWFV TESKHLSKPP
481 RDWFPHIKDA NNDTAYIEYK TCKDGSVLGV TVTRTALLTH CQALTQACGY TEAETIVNVL
541 DFKKDVGLWH GILTSVMNMM HVISIPYSLM KVNPLSWIQK VCQYKAKVAC VKSRDMHWAL
601 VAHRDQRDIN LSSLRMLIVA DGANPWSISS CDAFLNVFQS KGLRQEVICP CASSPEALTV
661 AIRRPTDDSN QPPGRGVLSM HGLTYGVIRV DSEEKLSVLT VQDVGLVMPG AIMCSVKPDG
721 VPQLCRTDEI GELCVCAVAT GTSYYGLSGM TKNTFEVFPM TSSGAPISEY PFIRTGLLGF
781 VGPGGLVFVV GKMDGLMVVS GRRHNADDIV ATALAVEPMK FVYRGRIAVF SVTVLHDERI
841 VIVAEQRPDS TEEDSFQWMS RVLQAIDSIH QVGVYCLALV PANTLPKTPL GGIHLSETKQ
901 LFLEGSLHPC NVLMCPHTCV TNLPKPRQKQ PEIGPASVMV GNLVSGKRIA QASGRDLGQI
961 EDNDQARKFL FLSEVLQWRA QTTPDHILYT LLNCRGAIAN SLTCVQLHKR AEKIAVMLME
1021 RGHLQDGDHV ALVYPPGIDL IAAFYGCLYA GCVPITVRPP HPQNIATTLP TVKMIVEVSR
1081 SACLMTTQLI CKLLRSREAA AAVDVRTWPL ILDTDDLPKK RPAQICKPCN PDTLAYLDFS
1141 VSTTGMLAGV KMSHAATSAF CRSIKLQCEL YPSREVAICL DPYCGLGFVL WCLCSVYSGH
1201 QSILIPPSEL ETNPALWLLA VSQYKVRDTF CSYSVMELCT KGLGSQTESL KARGLDLSRV
1261 RTCVVVAEER PRIALTQSFS KLFKDLGLHP RAVSTSFGCR VNLAICLQGT SGPDPTTVYV
1321 DMRALRHDRV RLVERGSPHS LPLMESGKIL PGVRIIIANP ETKGPLGDSH LGEIWVHSAH
1381 NASGYFTIYG DESLQSDHFN SRLSFGDTQT IWARTGYLGF LRRTELTDAN GERHDALYVV
1441 GALDEAMELR GMRYHPIDIE TSVIRAHKSV TECAVFTWTN LLVVVVELDG SEQEALDLVP
1501 LVTNVVLEEH YLIVGVVVVV DIGVIPINSR GEKQRMHLRD GFLADQLDPI YVAYNM
<210>3
<211>21
<212>DNA
<213> Artificial sequence
<220>
<223> DIP2C Gene-specific amplification primer 1
<400>3
agggcagcatcaatatggagc
<210>4
<211>19
<212>DNA
<213> Artificial sequence
<220>
<223> DIP2C Gene-specific amplification primer 2
<400>4
ctctgcgtagaggacgagg
<210>5
<211>25
<212>DNA
<213> Artificial sequence
<220>
<223>MO1
<400>5
tctagaatcaggtgtgaagctcacc
<210>6
<211>24
<212>DNA
<213> Artificial sequence
<220>
<223>MO2
<400>6
gcggtccgccattgtccgttcaaa
<210>7
<211>24
<212>DNA
<213> Artificial sequence
<220>
<223>MO3
<400>7
cctcttacctcagttacaatttata
<210>8
<211>24
<212>DNA
<213> Artificial sequence
<220>
<223> detection Probe
<400>8
ccagcaaacaccctccccaaaacc
Claims (10)
- The application of the DIP2C gene in a detection product of congenital heart disease.
- 2. The use of claim 1, wherein said product comprises a reagent for detecting congenital heart disease by detecting the expression level of DIP2C gene, DIP2C gene, mutation in DIP2C gene or mutation in the expression product of DIP2C gene in a biological sample.
- 3. The use of claim 2, wherein the product is detected by at least one of direct nucleic acid sequencing, nucleic acid hybridization, nucleic acid amplification, nucleic acid probe technology, or immunoassay.
- 4. Use according to claim 2, wherein the product comprises a formulation, a chip or a kit.
- 5. Use according to claim 3, wherein the test sample of the product is peripheral blood.
- 6. The use of claim 4, wherein the kit comprises at least one pair of DIP2C gene-specific amplification primer pairs, a PCR reaction solution, and at least one nucleic acid probe.
- 7. The use according to claim 6, wherein the nucleic acid probe is SYBR Green I, a Taqman probe, a molecular beacon, a hybridization probe or a composite probe.
- 8. The use of claim 6, wherein said pair of DIP2C gene-specific amplification primers has the nucleotide sequences shown in SEQ ID No.3 and SEQ ID No. 4.
- 9. A method for constructing an animal model of congenital heart disease, comprising administering a DIP2C inhibitor to a culture system, wherein the culture system comprises a cell system, a subcellular system, a solution system, a tissue system, an organ system, or an animal system. .
- 10. The method of claim 9, wherein a dip2ca gene inhibitor is injected into zebrafish embryos, said inhibitor being an antisense morpholine antisense oligonucleotide having the sequence of SEQ ID No.5 or SEQ ID No. 6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910735521.4A CN110804657A (en) | 2019-08-09 | 2019-08-09 | Application of DIP2C gene in congenital heart disease diagnosis product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910735521.4A CN110804657A (en) | 2019-08-09 | 2019-08-09 | Application of DIP2C gene in congenital heart disease diagnosis product |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110804657A true CN110804657A (en) | 2020-02-18 |
Family
ID=69487457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910735521.4A Pending CN110804657A (en) | 2019-08-09 | 2019-08-09 | Application of DIP2C gene in congenital heart disease diagnosis product |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110804657A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113388673A (en) * | 2021-04-28 | 2021-09-14 | 广东省人民医院 | Application of long noncoding RNA CARMEN |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945305A (en) * | 1996-09-19 | 1999-08-31 | Cedars-Sinai Medical Center | Nucleic acid encoding congenital heart disease protein and products related thereto |
CN103374625A (en) * | 2012-04-27 | 2013-10-30 | 中国科学院上海生命科学研究院 | Congenital heart disease related gene DLC1 and application thereof |
CN103374628A (en) * | 2012-04-27 | 2013-10-30 | 中国科学院上海生命科学研究院 | Congenital heart defect (CHD)-related gene family with sequence similarity 71, member A (FAM71A) and application thereof |
CN103374627A (en) * | 2012-04-27 | 2013-10-30 | 中国科学院上海生命科学研究院 | Congenital heart defect (CHD)-related gene polycystic kidney disease 1 like l (PKD1L1) and application thereof |
CN107653309A (en) * | 2017-08-30 | 2018-02-02 | 广东省心血管病研究所 | Applications of the MIR135HG in cardiovascular system is regulated and controled |
-
2019
- 2019-08-09 CN CN201910735521.4A patent/CN110804657A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945305A (en) * | 1996-09-19 | 1999-08-31 | Cedars-Sinai Medical Center | Nucleic acid encoding congenital heart disease protein and products related thereto |
CN103374625A (en) * | 2012-04-27 | 2013-10-30 | 中国科学院上海生命科学研究院 | Congenital heart disease related gene DLC1 and application thereof |
CN103374628A (en) * | 2012-04-27 | 2013-10-30 | 中国科学院上海生命科学研究院 | Congenital heart defect (CHD)-related gene family with sequence similarity 71, member A (FAM71A) and application thereof |
CN103374627A (en) * | 2012-04-27 | 2013-10-30 | 中国科学院上海生命科学研究院 | Congenital heart defect (CHD)-related gene polycystic kidney disease 1 like l (PKD1L1) and application thereof |
CN107653309A (en) * | 2017-08-30 | 2018-02-02 | 广东省心血管病研究所 | Applications of the MIR135HG in cardiovascular system is regulated and controled |
Non-Patent Citations (3)
Title |
---|
MARLENE EGGERT等: "A new familial case of microdeletion syndrome 10p15.3--European Journal of Medical GeneticsApril 2016", 《EUROPEAN JOURNAL OF MEDICAL GENETICS》, vol. 59, no. 4, 30 April 2016 (2016-04-30), pages 179 * |
李光明: "用斑马鱼模型研究基因CXXC5在心脏发育中的作用", 《中国博士学位论文全文数据库 基础科学辑》, no. 03, 15 March 2015 (2015-03-15), pages 37 * |
陈文杰等: "全外显子测序检测10p15.3微缺失综合征一例", 《中华医学遗传学杂志》, vol. 36, no. 04, 10 April 2019 (2019-04-10), pages 331 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113388673A (en) * | 2021-04-28 | 2021-09-14 | 广东省人民医院 | Application of long noncoding RNA CARMEN |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004121218A (en) | Method for testing bronchial asthma or chronic obstructive pulmonary disease | |
WO2006009629A2 (en) | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same | |
KR101873249B1 (en) | Method for diagnosing dementia using blood-derived cellular gene expression pattern | |
CN103384832A (en) | Compositions and methods for diagnosing and treating kidney disorders in a feline | |
FR3037657A1 (en) | METHOD OF DIAGNOSING DISORDERS CAUSED BY FETAL ALCOHOLIZATION | |
JPWO2017195809A1 (en) | Pro-inflammatory factor expression inhibitor, method for screening active ingredient thereof, expression cassette useful for the method, diagnostic agent, and diagnostic method | |
US20230054595A1 (en) | Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same | |
CN110804657A (en) | Application of DIP2C gene in congenital heart disease diagnosis product | |
KR20170041955A (en) | Mutant Genes as Diagnosis Marker for Amyotrophic Lateral Sclerosis and Diagnosis Method Using the Same | |
KR101418139B1 (en) | Compisition and method for diagnosting sex of Pa-ralichthyidae | |
Phillipps et al. | Prolactin regulation of insulin‐like growth factor 2 gene expression in the adult mouse choroid plexus | |
CN108753790B (en) | BAVM-associated gene markers and mutations thereof | |
CN108239642B (en) | Adipocyte differentiation related long non-coding RNA and application thereof | |
CN111471683B (en) | Application of miR-93-5p as marker for diagnosing and treating gastric cancer | |
JPWO2006129881A1 (en) | Bone and joint disease prophylactic / therapeutic agent and screening method thereof | |
JPWO2002050269A1 (en) | Testing methods for allergic diseases | |
CN118360380A (en) | Application of BAZ1B as gene marker in preparation of product for detecting aortic stenosis | |
KR102011182B1 (en) | Up-regulated genes in pterygium and use thereof | |
WO2014020070A1 (en) | Tif1-gamma for treating and diagnosing inflammatory diseases | |
CN118326058B (en) | Marker of iPSC in iNK cells and application thereof | |
KR102256859B1 (en) | Composition for diagnosing Alzheimer's disease | |
JP4214235B2 (en) | Type 2 diabetes diagnosis kit | |
KR101727750B1 (en) | Composition for diagnosing ischemia compriging sweet-taste receptor genes | |
KR102158009B1 (en) | Use of 14-3-3 gamma as attention deficit/hyperactivity disorder(ADHD) diagnostic marker | |
JPWO2002026962A1 (en) | Testing methods for allergic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |